公司概述
Insmed Incorporated is a biotechnology enterprise dedicated to the research, development, and commercialization of therapies designed for patients suffering from serious and rare diseases across the United States, Europe, Japan, and international markets. The company focuses on specific indications such as the treatment of refractory nontuberculous mycobacterial lung infections with its ARIKAYCE product while simultaneously advancing a phase 3 clinical trial program. Operating within the Healthcare sector and the Biotechnology industry, Insmed functions in a high-risk environment where capital-intensive research is required to bring novel drugs to market, distinguishing it from mature pharmaceutical firms with established cash flows. As of the latest reporting period, the company holds a substantial market capitalization of $34.45 billion and generates annual revenue of $606.42 million, supported by a workforce of 1,664 employees. These valuation and revenue figures indicate that the market assigns a significant premium to Insmed's pipeline, reflecting high expectations for future success in its rare disease indications despite the current lack of profitability.
财务健康
Insmed reported a trailing twelve-month revenue of $606.42 million, yet it recorded a net loss of $1,276,775,040, revealing a cost structure where non-operating expenses or significant impairment charges are eroding profitability far beyond the level of operating costs alone. The company's EBITDA for the same period stood at -$980,464,000, indicating that earnings before interest, taxes, depreciation, and amortization are currently insufficient to cover its operational outflows. Free cash flow was -$534,054,880, which suggests that the company is burning cash rapidly to fund its development activities and has limited financial flexibility to sustain operations without external financing or asset monetization. The gross margin stands at 79.7%, demonstrating strong pricing power and high-value manufacturing characteristics typical of specialty biotechnology products, while the operating margin of -94.6% and profit margin of -210.5% highlight severe inefficiencies or massive one-time charges impacting the bottom line. The balance sheet shows a cash position of $1.43 billion against total debt of $749.54 million, resulting in a debt-to-equity ratio of 101.43%, which classifies the company as highly leveraged relative to its equity base. Despite the leverage, the current ratio of 3.83 indicates a robust ability to meet short-term obligations with liquid assets, providing a buffer against immediate liquidity crises. Furthermore, the return on equity is -249.3% and the return on assets is -29.0%, metrics that reveal management has yet to generate positive returns on shareholder capital or total assets, a common characteristic for pre-revenue or late-stage clinical biotechnology companies still in the investment phase.
估值评估
The trailing twelve-month P/E ratio is N/A due to negative net income, whereas the forward P/E is listed at 218.14, implying that the market prices the stock based on anticipated future earnings that are not yet realized. The price-to-book ratio is 46.27, indicating that the stock trades at a massive premium of over 46 times its book value, which suggests investors are pricing in significant future growth potential or proprietary asset value not captured on the balance sheet. Alternative valuation metrics show a price-to-sales ratio of 56.80 and an EV/EBITDA of -34.39, further emphasizing that traditional profitability-based multiples are inapplicable and that valuation relies entirely on sales growth and pipeline potential. The stock has traded within a 52-week range bounded by a high of $212.75 and a low of $60.40, meaning the current price sits in a volatile position relative to its recent trading history. The beta value of 1.10 indicates that the stock's price volatility is 10% higher than the broader market, reflecting the inherent high risk associated with biotechnology equities and the specific uncertainties surrounding Insmed's clinical trial outcomes.
Growth & Income
Revenue growth year-over-year reached 152.6%, signaling a dramatic expansion in top-line sales, likely driven by market penetration of existing products or the initiation of new commercial activities, while earnings growth is N/A due to the company's ongoing losses. Since the company does not pay dividends with a 0.0% payout ratio and no dividend yield, the entire earnings profile is directed toward reinvesting capital into research and development rather than returning cash to shareholders. The absence of dividend payments confirms that Insmed prioritizes funding its clinical trials and expanding its commercial footprint over income generation for investors. Consequently, the overall growth and income profile is characterized by aggressive revenue expansion coupled with significant cash consumption and no current income distribution, positioning the asset as a pure-play growth investment dependent on future commercial milestones.